ZURICH, Nov 10 (Reuters) - Swiss drugmaker Novartis AG (NOVN.VX: Quote, Profile, Research) will not pay more royalties for asthma drug Xolair if U.S. biotech firm Genentech Inc. (DNA.N: Quote, Profile, Research) buys Tanox Inc. (TNOX.O: Quote, Profile, Research) as planned.
